Status:

COMPLETED

A Study of Three Modified-Release Formulations of RO4917523 in Healthy Volunteers

Lead Sponsor:

Hoffmann-La Roche

Conditions:

Healthy Volunteer

Eligibility:

All Genders

18-55 years

Phase:

PHASE1

Brief Summary

This single-center, open label, randomized, 3-period cross-over study will compare 3 modified-release formulations of RO4917523 in healthy volunteers. Subjects will be randomized to one of six sequenc...

Eligibility Criteria

Inclusion

  • Healthy male and female volunteers, 18 - 55 years of age inclusive Healthy status will be defined by absence in evidence of any active or chronic disease following a detailed medical and surgical history and a complete physical examination
  • Body mass index (BMI) of 18 to 30 kg/m2, inclusive, and body weight of at least 50 kg
  • Females of child-bearing potential must agree to use effective contraception as defined by protocol
  • Non-smoker for at least 90 days prior to dosing on Day 1

Exclusion

  • History or presence of a clinically significant psychiatric condition as defined by protocol
  • Participation in an clinical study with an investigational drug within 60 days or 5 times the half-life (whichever is longer) preceding first administration of study drug. Participation in more than 3 other drug studies within 10 months preceding first administration of study drug.
  • Clinically significant disease or disorder
  • Personal or family history of long QT syndrome or sudden death
  • Any suspicion or history of alcohol and/or other substance abuse or dependence in the last 6 months
  • Subject likely to need concomitant medication during the study (including for dental conditions), except for hormonal contraception or HRT
  • Pregnant or lactating women, or women who intend to become pregnant during the course of the study
  • Positive for hepatitis B, hepatitis C or HIV infection
  • Any confirmed significant allergic reactions against any drug, or multiple allergies

Key Trial Info

Start Date :

June 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2013

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT01873508

Start Date

June 1 2013

End Date

August 1 2013

Last Update

September 10 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Marlton, New Jersey, United States, 08053